Vol 7, No 4 (2022)
Review article
Published online: 2022-11-22

open access

Page views 3421
Article views/downloads 364
Get Citation

Connect on Social Media

Connect on Social Media

Granulocyte transfusion vs. neutropenia — is there a chance to win this battle?

Artur Szumowski12, Piotr Marek Radziwon12
Medical Research Journal 2022;7(4):321-332.


Bacterial and fungal infections remain a significant cause of morbidity and mortality in patients with prolonged severe neutropenia that results from the treatment of an underlying haematological malignancy. Granulocyte transfusions have been broadly used to prevent and/or treat life-threatening infections in these patients. The purpose of this review was to answer the question, “Are granulocyte transfusions effective in combating hazardous infections in haematology/oncology patients with neutropenia?”.

Article available in PDF format

View PDF Download PDF file


  1. Ang AL, Linn YC. Treatment of severe neutropenic sepsis with granulocyte transfusion in the current era - experience from an adult haematology unit in Singapore. Transfus Med. 2011; 21(1): 13–24.
  2. Harris DJ. The resurgence of granulocyte transfusions. J Infus Nurs. 2009; 32(6): 323–329.
  3. Brecher G, Wilbur KM, Cronkite EP. Transfusion of separated leukocytes into irradiated dogs with aplastic marrows. Proc Soc Exp Biol Med. 1953; 84(1): 54–56.
  4. Dale DC, Reynolds HY, Pennington JE, et al. Experimental Pseudomonas pneumonia in leukopenic dogs: comparison of therapy with antibiotics and granulocyte transfusions. Blood. 1976; 47(5): 869–876.
  5. Ruthe RC, Andersen BR, Cunningham BL, et al. Efficacy of granulocyte transfusions in the control of systemic candidiasis in the leukopenic host. Blood. 1978; 52(3): 493–498.
  6. Freirich EJ, Levin RH, Whang J, et al. The function and fate of transfused leukocytes from donors with chronic myelocytic leukemia in leukopenic recipients. Ann N Y Acad Sci. 1964; 113: 1081–1089.
  7. Stanworth SJ, Massey E, Hyde C, et al. Granulocyte transfusions for treating infections in patients with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev. 2005(3): CD005339.
  8. Grow WB, Moreb JS, Roque D, et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant. 2002; 29(1): 15–19.
  9. Bearden 3rd JD, Coltman CA, Ratkin GA. Hydroxyethyl starch and prednisone as adjuncts to granulocyte collection. Transfusion. 1977; 17(2): 141–146.
  10. Iacone A, Di Bartolomeo P, Di Girolamo G, et al. Hydroxyethyl starch and steroid improved collection of normal granulocytes with continuous flow centrifugation gravity leukapheresis. Haematologica. 1981; 66(5): 645–655.
  11. Mishler JM, Hester JP, Huestis DW, et al. Dosage and scheduling regimens for erythrocyte-sedimenting macromolecules. J Clin Apher. 1983; 1(3): 130–143.
  12. Glasser L, Huestis DW. Characteristics of stored granulocytes collected from donors stimulated with dexamethasone. Transfusion. 1979; 19(1): 53–56.
  13. Chanock S, Gorlin J. Granulocyte transfusions. Time for a second look. Infect Dis Clin North Am. 1996; 10(2): 327–343.
  14. Stroncek DF, Leitman SF. Granulocyte transfusions: a review. Immunohematology. 1998; 14(3): 101–108.
  15. Marfin AA, Price TH. Granulocyte transfusion therapy. J Intensive Care Med. 2015; 30(2): 79–88.
  16. Mary JY. Normal human granulopoiesis revisited. II. Bone marrow data. Biomed Pharmacother. 1985; 39(2): 66–77.
  17. Manz MG, Boettcher S. Emergency granulopoiesis. Nat Rev Immunol. 2014; 14(5): 302–314.
  18. Borregaard N. Neutrophils, from marrow to microbes. Immunity. 2010; 33(5): 657–670.
  19. Curi R, Levada-Pires AC, Silva EB, et al. The critical role of cell metabolism for essential neutrophil functions. Cell Physiol Biochem. 2020; 54(4): 629–647.
  20. Summers C, Rankin SM, Condliffe AM, et al. Neutrophil kinetics in health and disease. Trends Immunol. 2010; 31(8): 318–324.
  21. Chan YK, Tsai MH, Huang DC, et al. Leukocyte nucleus segmentation and nucleus lobe counting. BMC Bioinformatics. 2010; 11: 558.
  22. Cowland JB, Borregaard N. Granulopoiesis and granules of human neutrophils. Immunol Rev. 2016; 273(1): 11–28.
  23. Faurschou M, Borregaard N. Neutrophil granules and secretory vesicles in inflammation. Microbes Infect. 2003; 5(14): 1317–1327.
  24. Nüsse O, Lindau M. The dynamics of exocytosis in human neutrophils. J Cell Biol. 1988; 107(6 Pt 1): 2117–2123.
  25. Borregaard N, Sørensen OE, Theilgaard-Mönch K. Neutrophil granules: a library of innate immunity proteins. Trends Immunol. 2007; 28(8): 340–345.
  26. Kumar R, Azam S, Sullivan JM, et al. Brain ischemia and reperfusion activates the eukaryotic initiation factor 2alpha kinase, PERK. J Neurochem. 2001; 77(5): 1418–1421.
  27. Selvatici R, Falzarano S, Mollica A, et al. Signal transduction pathways triggered by selective formylpeptide analogues in human neutrophils. Eur J Pharmacol. 2006; 534(1-3): 1–11.
  28. Witko-Sarsat V, Rieu P, Descamps-Latscha B, et al. Neutrophils: molecules, functions and pathophysiological aspects. Lab Invest. 2000; 80(5): 617–653.
  29. Hatanaka E, Shimomi FM, Curi R, et al. Sodium chloride inhibits cytokine production by lipopolysaccharide-stimulated human neutrophils and mononuclear cells. Shock. 2007; 27(1): 32–35.
  30. Levada-Pires AC, Lambertucci RH, Mohamad M, et al. Exercise training raises expression of the cytosolic components of NADPH oxidase in rat neutrophils. Eur J Appl Physiol. 2007; 100(2): 153–160.
  31. de Oliveira S, Rosowski EE, Huttenlocher A. Neutrophil migration in infection and wound repair: going forward in reverse. Nat Rev Immunol. 2016; 16(6): 378–391.
  32. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004; 303(5663): 1532–1535.
  33. Mastronardi R, Cleophax S, Begué S, et al. [Preparation of pooled granulocytes concentrates from whole blood buffy coats (PGC) as an alternative to apheresis]. Transfus Clin Biol. 2019; 26(3): 164–170.
  34. Bensinger WI, Price TH, Dale DC, et al. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood. 1993; 81(7): 1883–1888.
  35. Caspar CB, Seger RA, Burger J, et al. Effective stimulation of donors for granulocyte transfusions with recombinant methionyl granulocyte colony-stimulating factor. Blood. 1993; 81(11): 2866–2871.
  36. Leavey PJ, Thurman G, Ambruso DR. Functional characteristics of neutrophils collected and stored after administration of G-CSF. Transfusion. 2000; 40(4): 414–419.
  37. Bux J, Cassens U, Dielschneider T, et al. Tolerance of granulocyte donors towards granulocyte colony-stimulating factor stimulation and of patients towards granulocyte transfusions: results of a multicentre study. Vox Sang. 2003; 85(4): 322–325.
  38. de la Rubia J, de Arriba F, Arbona C, et al. Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry. Haematologica. 2008; 93(5): 735–740.
  39. Hölig K. G-CSF in healthy allogeneic stem cell donors. Transfus Med Hemother. 2013; 40(4): 225–235.
  40. Toy P, Gajic O, Bacchetti P, et al. Transfusion-related acute lung injury: incidence and risk factors. Blood. 2012; 119(7): 1757–1767.
  41. Gutierrez-Delgado F, Bensinger W. Safety of granulocyte colony-stimulating factor in normal donors. Curr Opin Hematol. 2001; 8(3): 155–160.
  42. Wiedermann CJ, Joannidis M. Accumulation of hydroxyethyl starch in human and animal tissues: a systematic review. Intensive Care Med. 2014; 40(2): 160–170.
  43. Jendiroba DB, Freireich EJ. Granulocyte transfusions: from neutrophil replacement to immunereconstitution. Blood Rev. 2000; 14(4): 219–227.
  44. Hubel K, Rodger E, Gaviria JM, et al. Effective storage of granulocytes collected by centrifugation leukapheresis from donors stimulated with granulocyte-colony-stimulating factor. Transfusion. 2005; 45(12): 1876–1889.
  45. Schmitt A, Reinhardt P, Schmitt M, et al. Functional state of steroid- versus g-csf-mobilized granulocytes: considerations about the storage of granulocyte concentrates for neutropenic patients. Transfus Med Hemother. 2002; 29: 57–64.
  46. Patrone F, Dallegri F, Brema F, et al. In vitro function of chronic myelocytic leukemia granulocytes. Effects of irradiation and storage. Tumori. 1979; 65(1): 27–37.
  47. Netelenbos T, Massey E, de Wreede LC, et al. The burden of invasive infections in neutropenic patients: incidence, outcomes, and use of granulocyte transfusions. Transfusion. 2019; 59(1): 160–168.
  48. Pammi M, Brocklehurst P. Granulocyte transfusions for neonates with confirmed or suspected sepsis and neutropenia. Cochrane Database Syst Rev. 2011; 2011(10): CD003956.
  49. Seidel MG, Peters C, Wacker A, et al. Randomized phase III study of granulocyte transfusions in neutropenic patients. Bone Marrow Transplant. 2008; 42(10): 679–684.
  50. Price TH. Granulocyte transfusion: current status. Semin Hematol. 2007; 44(1): 15–23.
  51. Solomou EE, Salamaliki C, Lagadinou M. How to make the right diagnosis in neutropenia. Clin Hematol Int. 2021; 3(2): 41–46.
  52. Newburger PE, Dale DC. Evaluation and management of patients with isolated neutropenia. Semin Hematol. 2013; 50(3): 198–206.
  53. Rider NL, Jameson MB, Creech CB. Chronic granulomatous disease: epidemiology, pathophysiology, and genetic basis of disease. J Pediatric Infect Dis Soc. 2018; 7(suppl_1): S2–S5.
  54. Lozano ML, Rivera J, Sánchez-Guiu I, et al. Towards the targeted management of Chediak-Higashi syndrome. Orphanet J Rare Dis. 2014; 9: 132.
  55. Drewniak A, Kuijpers TW. Granulocyte transfusion therapy: randomization after all? Haematologica. 2009; 94(12): 1644–1648.
  56. Higby DJ, Yates JW, Henderson ES, et al. Filtration leukapheresis for granulocyte transfusion therapy. Clinical and laboratory studies. N Engl J Med. 1975; 292(15): 761–766.
  57. van de Wetering MD, Weggelaar N, Offringa M, et al. Granulocyte transfusions in neutropaenic children: a systematic review of the literature. Eur J Cancer. 2007; 43(14): 2082–2092.
  58. Dutcher JP, Kendall J, Norris D, et al. Granulocyte transfusion therapy and amphotericin B: adverse reactions? Am J Hematol. 1989; 31(2): 102–108.
  59. Wright DG, Robichaud KJ, Pizzo PA, et al. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med. 1981; 304(20): 1185–1189.
  60. Bow EJ, Schroeder ML, Louie TJ. Pulmonary complications in patients receiving granulocyte transfusions and amphotericin B. Can Med Assoc J. 1984; 130(5): 593–597.
  61. Segal BH, Leto TL, Gallin JI, et al. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore). 2000; 79(3): 170–200.
  62. Ajitkumar A, Yarrarapu SNS, Ramphul K. Chediak Higashi syndrome. StatPearls, Treasure Island 2022.
  63. Sharma S, Sharma P, Tyler LN. Transfusion of blood and blood products: indications and complications. Am Fam Physician. 2011; 83(6): 719–724.
  64. Goel R, Tobian AAR, Shaz BH. Noninfectious transfusion-associated adverse events and their mitigation strategies. Blood. 2019; 133(17): 1831–1839.
  65. Fung MK, Eder AF, Spitalnik SL. Technical Manual. AABB, Bethesda 2017: 457-488, 505-526,–569-598.
  66. Bandarenko N, King K. Blood transfusion therapy: a physician’s handbook. AABB, Bethesda 2017: 1-52, 141-170, 221-256.
  67. Popovsky MA. Transfusion Reactions. AABB, Bethesda 2012: 1-288, 327-338.
  68. Delaney M, Wendel S, Bercovitz R, et al. Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Transfusion reactions: prevention, diagnosis, and treatment. Lancet. 2016; 388(10061): 2825–2836.
  69. Sweeney J, Lozano M. Platelet Transfusion Therapy. AABB, Bethesda 2013: 229-320, 371-398, 493-566.
  70. Busch MP, Bloch EM, Kleinman S. Prevention of transfusion-transmitted infections. Blood. 2019; 133(17): 1854–1864.
  71. Eder AF, Goldman M. How do I investigate septic transfusion reactions and blood donors with culture-positive platelet donations? Transfusion. 2011; 51(8): 1662–1668.
  72. Bolton-Maggs PHB. Conference report: the 2015 SHOT symposium and report - what's new? Transfus Med. 2015; 25(5): 295–298.
  73. Murphy EL, Kwaan N, Looney MR, et al. TRALI Study Group. Risk factors and outcomes in transfusion-associated circulatory overload. Am J Med. 2013; 126(4): 357.e29–357.e38.
  74. Piccin A, Cronin M, Brady R, et al. Transfusion-associated circulatory overload in Ireland: a review of cases reported to the National Haemovigilance Office 2000 to 2010. Transfusion. 2015; 55(6): 1223–1230.
  75. Semple JW, Rebetz J, Kapur R. Transfusion-associated circulatory overload and transfusion-related acute lung injury. Blood. 2019; 133(17): 1840–1853.
  76. Popovsky MA. Transfusion-associated circulatory overload: the plot thickens. Transfusion. 2009; 49(1): 2–4.
  77. Kim KiH, Lim HJ, Kim JS, et al. Therapeutic granulocyte transfusions for the treatment of febrile neutropenia in patients with hematologic diseases: a 10-year experience at a single institute. Cytotherapy. 2011; 13(4): 490–498.
  78. Raad II, Chaftari AM, Al Shuaibi MM, et al. Granulocyte transfusions in hematologic malignancy patients with invasive pulmonary aspergillosis: outcomes and complications. Ann Oncol. 2013; 24(7): 1873–1879.
  79. Safdar A, Rodriguez G, Zuniga J, et al. Use of healthy-donor granulocyte transfusions to treat infections in neutropenic patients with myeloid or lymphoid neoplasms: experience in 74 patients treated with 373 granulocyte transfusions. Acta Haematol. 2014; 131(1): 50–58.
  80. Wang H, Wu Y, Fu R, et al. Granulocyte transfusion combined with granulocyte colony stimulating factor in severe infection patients with severe aplastic anemia: a single center experience from China. PLoS ONE. 2014; 9(2): e88148.
  81. Kadri SS, Remy KE, Strich JR, et al. Role of granulocyte transfusions in invasive fusariosis: systematic review and single-center experience. Transfusion. 2015; 55(9): 2076–2085.
  82. Price TH, Boeckh M, Harrison RW, et al. Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection. Blood. 2015; 126(18): 2153–2161.
  83. Teofili L, Valentini CG, Di Blasi R, et al. Dose-dependent effect of granulocyte transfusions in hematological patients with febrile neutropenia. PLoS One. 2016; 11(8): e0159569.
  84. Garg A, Gupta A, Mishra A, et al. Role of granulocyte transfusions in combating life-threatening infections in patients with severe neutropenia: Experience from a tertiary care centre in North India. PLoS One. 2018; 13(12): e0209832.